

Joanna J Phillips

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4210309/publications.pdf>

Version: 2024-02-01

148
papers

10,669
citations

41344

49
h-index

37204

96
g-index

150
all docs

150
docs citations

150
times ranked

15825
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring Sulfatase Expression and Invasion in Glioblastoma. <i>Methods in Molecular Biology</i> , 2022, 2303, 415-425.	0.9	1
2	Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging. <i>Neuro-Oncology</i> , 2022, 24, 639-652.	1.2	22
3	Cellular architecture of human brain metastases. <i>Cell</i> , 2022, 185, 729-745.e20.	28.9	69
4	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	32
5	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. <i>Neuro-Oncology</i> , 2022, 24, 1471-1481.	1.2	14
6	Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. <i>Neuro-Oncology</i> , 2022, 24, 1749-1762.	1.2	10
7	In-Depth Matrisome and Glycoproteomic Analysis of Human Brain Glioblastoma Versus Control Tissue. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100216.	3.8	22
8	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. <i>Neurosurgery</i> , 2022, 90, 124-130.	1.1	17
9	Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma. <i>Acta Neuropathologica</i> , 2022, 143, 283-286.	7.7	5
10	Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. <i>Nature Genetics</i> , 2022, 54, 649-659.	21.4	93
11	CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma. <i>Clinical Cancer Research</i> , 2022, 28, 2898-2910.	7.0	16
12	Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 650-657.	1.7	5
13	Prognostic risk stratification of gliomas using deep learning in digital pathology images. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	3
14	A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection. <i>Neurosurgery</i> , 2021, 88, 202-210.	1.1	19
15	Heparan Sulfate Synthesized by <i>Ext1</i> Regulates Receptor Tyrosine Kinase Signaling and Promotes Resistance to EGFR Inhibitors in GBM. <i>Molecular Cancer Research</i> , 2021, 19, 150-161.	3.4	12
16	Development of novel monoclonal antibodies and immunoassays for sensitive and specific detection of SULF1 endosulfatase. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129802.	2.4	3
17	Synthesis and Screening of \pm -Xylosides in Human Glioblastoma Cells. <i>Molecular Pharmaceutics</i> , 2021, 18, 451-460.	4.6	5
18	Immune cell analysis of pilocytic astrocytomas reveals sexually dimorphic brain region-specific differences in T-cell content. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab068.	0.7	2

#	ARTICLE	IF	CITATIONS
19	The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab085.	0.7	10
20	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTcâ€042). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28879.	1.5	24
21	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). <i>Acta Neuropathologica</i> , 2021, 141, 605-617.	7.7	36
22	Overcoming the inhibitory microenvironment surrounding oligodendrocyte progenitor cells following experimental demyelination. <i>Nature Communications</i> , 2021, 12, 1923.	12.8	16
23	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47
24	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade <i>IDH</i>-mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1872-1884.	1.2	48
25	5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO) Tj ETQq1 1 0.784314 rgBT /Overloc	3.7	19
26	Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. <i>Neuro-Oncology</i> , 2021, 23, 1974-1976.	1.2	12
27	The evolution of alternative splicing in glioblastoma under therapy. <i>Genome Biology</i> , 2021, 22, 48.	8.8	23
28	Non-invasive assessment of telomere maintenance mechanisms in brain tumors. <i>Nature Communications</i> , 2021, 12, 92.	12.8	21
29	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. <i>Science Translational Medicine</i> , 2021, 13, eabc0497.	12.4	29
30	ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. <i>Genome Biology</i> , 2021, 22, 311.	8.8	25
31	Reply to Stummer, W.; Thomas, C. Comment on "Hosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)" Experience at Two Specialized Centers. <i>Cancers</i> 2021, 13, 2540â€; <i>Cancers</i> , 2021, 13, 5705.	3.7	0
32	Highâ€grade neuroepithelial tumor with <i>BCOR</i> exon 15 internal tandem duplicationâ€a comprehensive clinical, radiographic, pathologic, and genomic analysis. <i>Brain Pathology</i> , 2020, 30, 46-62.	4.1	69
33	Loss of H3K27 trimethylation by immunohistochemistry is frequent in oligodendroglioma, IDH-mutant and 1p/19q-codeleted, but is neither a sensitive nor a specific marker. <i>Acta Neuropathologica</i> , 2020, 139, 597-600.	7.7	9
34	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. <i>Cell</i> , 2020, 183, 1962-1985.e31.	28.9	177
35	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. <i>Acta Neuropathologica Communications</i> , 2020, 8, 151.	5.2	35
36	Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa088.	0.7	16

#	ARTICLE	IF	CITATIONS
37	Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa078.	0.7	12
38	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa142.	0.7	35
39	Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features. <i>Acta Neuropathologica</i> , 2020, 139, 953-957.	7.7	18
40	MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. <i>Neuro-Oncology</i> , 2020, 22, 1580-1590.	1.2	55
41	Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 495.	7.1	325
42	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. <i>Acta Neuropathologica</i> , 2020, 139, 1071-1088.	7.7	50
43	The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. <i>Brain Pathology</i> , 2019, 29, 85-96.	4.1	88
44	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1565-1576.	4.1	11
45	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. <i>Acta Neuropathologica</i> , 2019, 138, 877-881.	7.7	21
46	The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. <i>Cancer Discovery</i> , 2019, 9, 1708-1719.	9.4	205
47	EGFR amplification status for clinical trial inclusion: where do we draw the line?. <i>Neuro-Oncology</i> , 2019, 21, 1215-1216.	1.2	1
48	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. <i>Cell Stem Cell</i> , 2019, 25, 433-446.e7.	11.1	56
49	Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. <i>Neuro-Oncology</i> , 2019, 21, 1164-1174.	1.2	12
50	High density is a property of slow-cycling and treatment-resistant human glioblastoma cells. <i>Experimental Cell Research</i> , 2019, 378, 76-86.	2.6	14
51	A pilot precision medicine trial for children with diffuse intrinsic pontine glioma—PNO003: A report from the Pacific Pediatric Neuro-Oncology Consortium. <i>International Journal of Cancer</i> , 2019, 145, 1889-1901.	5.1	84
52	Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. <i>Acta Neuropathologica</i> , 2019, 137, 851-854.	7.7	45
53	NIMG-42. RECURRENT TUMOR AND TREATMENT-INDUCED EFFECTS HAVE DIFFERENT MR SIGNATURES IN CONTRAST ENHANCING AND NON-ENHANCING LESIONS OF HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi170-vi170.	1.2	0
54	PATH-38. ROSETTE-FORMING GLIONEURONAL TUMOR IS DEFINED BY FGFR1 ACTIVATING ALTERATIONS WITH FREQUENT ACCOMPANYING PI3K AND MAPK PATHWAY MUTATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi151-vi152.	1.2	0

#	ARTICLE	IF	CITATIONS
55	IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi121-vi121.	1.2	0
56	GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi107-vi108.	1.2	0
57	ACTR-42. PI3K/mTOR PATHWAY ACTIVATION SELECTED PHASE II STUDY OF EVEROLIMUS (RAD001) WITH AND WITHOUT TEMOZOLOMIDE IN THE TREATMENT OF ADULT PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMA [NCT NCT02023905]. <i>Neuro-Oncology</i> , 2019, 21, vi22-vi23.	1.2	0
58	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. <i>PLoS ONE</i> , 2019, 14, e0219724.	2.5	25
59	The genetic landscape of gliomas arising after therapeutic radiation. <i>Acta Neuropathologica</i> , 2019, 137, 139-150.	7.7	57
60	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. , 2019, 14, e0219724.		0
61	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. , 2019, 14, e0219724.		0
62	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. , 2019, 14, e0219724.		0
63	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. , 2019, 14, e0219724.		0
64	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. <i>Nature Communications</i> , 2018, 9, 810.	12.8	56
65	A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. <i>Cancer Cell</i> , 2018, 33, 874-889.e7.	16.8	180
66	Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. <i>Acta Neuropathologica</i> , 2018, 135, 485-488.	7.7	54
67	2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas. <i>Cancer Research</i> , 2018, 78, 2290-2304.	0.9	42
68	Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. <i>Cell Reports</i> , 2018, 22, 3672-3683.	6.4	95
69	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 632-641.	1.2	33
70	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	7.0	68
71	Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF- κ B pathway activation. <i>Modern Pathology</i> , 2018, 31, 660-673.	5.5	76
72	PATH-09. CLINICAL CHARACTERISTICS OF ADULTS WITH H3 K27M-MUTANT GLIOMAS AT UCSF. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi160.	1.2	2

#	ARTICLE	IF	CITATIONS
73	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	1.2	0
74	ACTR-32. 5-ALA FLUORESCENCE IS A POWERFUL MARKER FOR DETECTION OF UNEXPECTED GLIOBLASTOMA TISSUE DURING SURGERY OF RADIOLOGICALLY SUSPECTED LOW-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi18-vi18.	1.2	0
75	NIMG-11. DIFFERENTIATING TREATMENT-INDUCED EFFECTS FROM TRUE RECURRENT HIGH GRADE GLIOMA USING MULTIPARAMETRIC MRI TECHNIQUES. <i>Neuro-Oncology</i> , 2018, 20, vi177-vi178.	1.2	0
76	A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma. <i>Nature Cell Biology</i> , 2018, 20, 1203-1214.	10.3	103
77	Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas. <i>Translational Oncology</i> , 2018, 11, 941-949.	3.7	8
78	Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. <i>Cancer & Metabolism</i> , 2018, 6, 3.	5.0	34
79	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 477-483.	2.9	82
80	An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice. <i>Neuro-Oncology</i> , 2018, 20, 1606-1615.	1.2	19
81	Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. <i>Neuro-Oncology</i> , 2017, 19, now176.	1.2	70
82	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. <i>Neuro-Oncology</i> , 2017, 19, now254.	1.2	155
83	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	1.2	217
84	Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma. <i>Cell Cycle</i> , 2017, 16, 765-775.	2.6	15
85	Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 171-179.	2.9	13
86	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. <i>Neuro-Oncology</i> , 2017, 19, 1135-1144.	1.2	236
87	Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. <i>Scientific Reports</i> , 2017, 7, 44792.	3.3	63
88	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. <i>Cancer Cell</i> , 2017, 31, 424-435.	16.8	138
89	Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. <i>Acta Neuropathologica</i> , 2017, 134, 961-963.	7.7	17
90	Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10743-10748.	7.1	109

#	ARTICLE	IF	CITATIONS
91	Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. <i>Cancer</i> , 2017, 123, 4631-4639.	4.1	43
92	Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion. <i>Molecular Cancer Research</i> , 2017, 15, 1623-1633.	3.4	29
93	Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. <i>Translational Oncology</i> , 2017, 10, 895-903.	3.7	15
94	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017, 32, 42-56.e6.	16.8	1,282
95	METB-11. HYPOXIA INDUCIBLE FACTOR 1± REPROGRAMS CHOLINE AND ETHANOLAMINE PHOSPHOLIPID METABOLISM IN MUTANT IDH1 GLIOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi130-vi130.	1.2	0
96	GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. <i>Oncotarget</i> , 2016, 7, 79101-79116.	1.8	39
97	CBIO-02. MUTANT IDH EXPRESSION DRIVES TERT PROMOTER REACTIVATION AS PART OF THE CELLULAR TRANSFORMATION PROCESS. <i>Neuro-Oncology</i> , 2016, 18, vi35-vi35.	1.2	0
98	MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS. <i>Neuro-Oncology</i> , 2016, 18, vi113-vi113.	1.2	0
99	NIMG-43. APPLICATION OF AN ADVANCED DIFFUSION-WEIGHTED MRI TECHNIQUE TO CHARACTERIZE GLIOMA MICROSTRUCTURE AND RELATIONSHIP TO HISTOPATHOLOGY. <i>Neuro-Oncology</i> , 2016, 18, vi134-vi134.	1.2	0
100	PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells. <i>International Journal of Cancer</i> , 2016, 139, 99-111.	5.1	25
101	MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1113-1122.	4.1	42
102	The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. <i>Academic Radiology</i> , 2016, 23, 1073-1082.	2.5	14
103	Protein Analysis of Glioblastoma Primary and Posttreatment Pairs Suggests a Mesenchymal Shift at Recurrence. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 925-935.	1.7	31
104	Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFN±Rko Mice. <i>Human Gene Therapy Clinical Development</i> , 2016, 27, 145-151.	3.1	9
105	Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. <i>Acta Neuropathologica</i> , 2016, 132, 757-760.	7.7	32
106	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 543-552.	2.9	90
107	Mutant IDH1 Expression Drives <i>TERT</i> Promoter Reactivation as Part of the Cellular Transformation Process. <i>Cancer Research</i> , 2016, 76, 6680-6689.	0.9	55
108	Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. <i>Cell</i> , 2016, 167, 1281-1295.e18.	28.9	207

#	ARTICLE	IF	CITATIONS
109	Tissue mechanics promote IDH1-dependent HIF1 α -tenascin C feedback to regulate glioblastoma aggression. <i>Nature Cell Biology</i> , 2016, 18, 1336-1345.	10.3	259
110	Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. <i>Brain</i> , 2016, 139, 3202-3216.	7.6	136
111	Missense-depleted regions in population exomes implicate ras superfamily nucleotide-binding protein alteration in patients with brain malformation. <i>Npj Genomic Medicine</i> , 2016, 1, .	3.8	41
112	Magnetic resonance analysis of malignant transformation in recurrent glioma. <i>Neuro-Oncology</i> , 2016, 18, 1169-1179.	1.2	28
113	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
114	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2016, 18, 557-564.	1.2	432
115	Proportional Upregulation of CD97 Isoforms in Glioblastoma and Glioblastoma-Derived Brain Tumor Initiating Cells. <i>PLoS ONE</i> , 2015, 10, e0111532.	2.5	19
116	Metabolic Reprogramming in Mutant IDH1 Glioma Cells. <i>PLoS ONE</i> , 2015, 10, e0118781.	2.5	67
117	Glycosylation Alterations in Lung and Brain Cancer. <i>Advances in Cancer Research</i> , 2015, 126, 305-344.	5.0	79
118	IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. <i>Cancer Research</i> , 2015, 75, 2999-3009.	0.9	106
119	ATCT-32A PHASE II STUDY OF TEMOZOLOMIDE IN THE TREATMENT OF ADULT PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2015, 17, v8.4-v9.	1.2	0
120	Practical Molecular Pathology and Histopathology of Embryonal Tumors. <i>Surgical Pathology Clinics</i> , 2015, 8, 73-88.	1.7	6
121	Numerical chromosomal instability mediates susceptibility to radiation treatment. <i>Nature Communications</i> , 2015, 6, 5990.	12.8	63
122	Toward precision medicine in glioblastoma: the promise and the challenges. <i>Neuro-Oncology</i> , 2015, 17, 1051-1063.	1.2	178
123	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. <i>Lancet Oncology</i> , The, 2015, 16, 569-582.	10.7	147
124	DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. <i>Cancer Cell</i> , 2015, 28, 307-317.	16.8	221
125	Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. <i>Cancer Research</i> , 2015, 75, 5355-5366.	0.9	33
126	SULF2, a heparan sulfate endosulfatase, is present in the blood of healthy individuals and increases in cirrhosis. <i>Clinica Chimica Acta</i> , 2015, 440, 72-78.	1.1	17

#	ARTICLE	IF	CITATIONS
127	Measuring Sulfatase Expression and Invasion in Glioblastoma. <i>Methods in Molecular Biology</i> , 2015, 1229, 507-516.	0.9	9
128	Glioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase. <i>PLoS ONE</i> , 2014, 9, e108289.	2.5	62
129	Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker of IDH1 Mutational Status in Glioma. <i>Cancer Research</i> , 2014, 74, 4247-4257.	0.9	77
130	Signals that regulate the oncogenic fate of neural stem cells and progenitors. <i>Experimental Neurology</i> , 2014, 260, 56-68.	4.1	15
131	Matrix regulators in neural stem cell functions. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 2520-2525.	2.4	40
132	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
133	<sc><i>PDGFRA</i></sc> Amplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in <sc>IDH</sc> 1 Mutant Glioblastoma. <i>Brain Pathology</i> , 2013, 23, 565-573.	4.1	83
134	Mass Spectral Profiling of Glycosaminoglycans from Histological Tissue Surfaces. <i>Analytical Chemistry</i> , 2013, 85, 10984-10991.	6.5	33
135	Non-invasive in vivo assessment of IDH1 mutational status in glioma. <i>Nature Communications</i> , 2013, 4, 2429.	12.8	118
136	Proteoglycans and their roles in brain cancer. <i>FEBS Journal</i> , 2013, 280, 2399-2417.	4.7	158
137	The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. <i>Modern Pathology</i> , 2013, 26, 1425-1432.	5.5	98
138	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. <i>Neuro-Oncology</i> , 2012, 14, 1146-1152.	1.2	85
139	Magnetic Resonance of 2-Hydroxyglutarate in <i>IDH1</i> -Mutated Low-Grade Gliomas. <i>Science Translational Medicine</i> , 2012, 4, 116ra5.	12.4	161
140	Increased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric Astrocytomas. <i>PLoS ONE</i> , 2012, 7, e43339.	2.5	142
141	VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex. <i>Cancer Cell</i> , 2012, 22, 21-35.	16.8	495
142	Heparan sulfate sulfatase SULF2 regulates PDGFR \pm signaling and growth in human and mouse malignant glioma. <i>Journal of Clinical Investigation</i> , 2012, 122, 911-922.	8.2	87
143	Novel therapeutic targets in the brain tumor microenvironment. <i>Oncotarget</i> , 2012, 3, 568-75.	1.8	16
144	Novel Therapeutic Targets in the Brain Tumor Microenvironment. <i>Oncotarget</i> , 2012, 3, 568-575.	1.8	27

#	ARTICLE	IF	CITATIONS
145	Novel regulation of PDGFR β activation in Glioblastoma. FASEB Journal, 2012, 26, 479.7.	0.5	0
146	Asymmetry-Defective Oligodendrocyte Progenitors Are Glioma Precursors. Cancer Cell, 2011, 20, 328-340.	16.8	200
147	Pituicytoma: Characterization of a Unique Neoplasm by Histology, Immunohistochemistry, Ultrastructure, and Array-Based Comparative Genomic Hybridization. Archives of Pathology and Laboratory Medicine, 2010, 134, 1063-1069.	2.5	51
148	Dandy-Walker Malformation Complex. Obstetrics and Gynecology, 2006, 107, 685-693.	2.4	36